Featured Research

from universities, journals, and other organizations

Promise for treating papillary thyroid cancer

Date:
October 16, 2013
Source:
American Thyroid Association
Summary:
Emerging data regarding vemurafenib, a BRAF-targeted inhibitor used with good effect for BRAF V600E mutation positive melanomas, are much anticipated.

Mutations in a gene that codes for the enzyme BRAF kinase have been associated with increased risk for papillary thyroid cancer (PTC). An early-stage clinical trial of the BRAF inhibitor vemurafenib resulted in either a partial response or stable disease in patients with PTC and BRAF mutations.

Related Articles


R. Dadu and colleagues from M. D. Anderson Cancer Center, Houston, TX, will report on a series of patients with advanced metastatic PTC and the V600E BRAF mutation who were treated with the selective BRAF inhibitor vemurafenib in a poster presentation at the upcoming 83rd Annual Meeting of the American Thyroid Association, October 16-20, in San Juan, Puerto Rico.

Three of 12 patients (25%) had a partial response to treatment (>30% reduction) and 75% had stable disease (of which 56% had a minor response) to treatment. In the poster "Efficacy and Tolerability of Vemurafenib in BRAFV600E Positive Papillary Thyroid Cancer (PTC)" the researchers report that the treatment was well tolerated.

BP Danysh and coworkers from M. D. Anderson Cancer Center explore why responses to vemurafenib are typically incomplete, drug resistance develops, and a patient's disease inevitably progresses despite treatment. In the poster "Effects of Activated Estrogen Receptors on Acquired BRAF Inhibitor Resistance in Papillary Thyroid Cancer (PTC)" they describe the role that estrogen receptors may have in acquired resistance to BRAF inhibitors. This may help explain the gender disparity in PTC (3:1 female:male ratio) and why the cancer is more prevalent among women of childbearing age.

Nearly 50% of papillary thyroid cancers in the U.S. are BRAF V600E mutation positive, and this characteristic has been exploited with the development of novel small molecule therapies that target BRAF for treating patients with advanced thyroid cancer," says Julie Ann Sosa, MD, Program Committee Co-Chair; Professor of Surgery and Medicine, Chief, Section of Endocrine Surgery, and Director of Health Services Research, Department of Surgery, Duke University School of Medicine; and Leader, Endocrine Neoplasia Diseases Group, Duke Cancer Institute and Duke Clinical Research Institute, Durham, NC. "Unfortunately, treatment effect can be short-lived. These emerging data regarding vemurafenib, a BRAF-targeted inhibitor used with good effect for BRAF V600E mutation positive melanomas, are much anticipated. Additional information regarding estrogen receptors and the extent of effect of BRAF-targeted inhibitors could be helpful in moving forward the development of new combinations of agents with more durable effect."


Story Source:

The above story is based on materials provided by American Thyroid Association. Note: Materials may be edited for content and length.


Cite This Page:

American Thyroid Association. "Promise for treating papillary thyroid cancer." ScienceDaily. ScienceDaily, 16 October 2013. <www.sciencedaily.com/releases/2013/10/131016095839.htm>.
American Thyroid Association. (2013, October 16). Promise for treating papillary thyroid cancer. ScienceDaily. Retrieved November 27, 2014 from www.sciencedaily.com/releases/2013/10/131016095839.htm
American Thyroid Association. "Promise for treating papillary thyroid cancer." ScienceDaily. www.sciencedaily.com/releases/2013/10/131016095839.htm (accessed November 27, 2014).

Share This


More From ScienceDaily



More Health & Medicine News

Thursday, November 27, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Ebola Leaves Orphans Alone in Sierra Leone

Ebola Leaves Orphans Alone in Sierra Leone

AFP (Nov. 27, 2014) — The Ebola epidemic sweeping Sierra Leone is having a profound effect on the country's children, many of whom have been left without any family members to support them. Duration: 01:02 Video provided by AFP
Powered by NewsLook.com
Experimental Ebola Vaccine Shows Promise In Human Trial

Experimental Ebola Vaccine Shows Promise In Human Trial

Newsy (Nov. 27, 2014) — A recent test of a prototype Ebola vaccine generated an immune response to the disease in subjects. Video provided by Newsy
Powered by NewsLook.com
Pet Dogs to Be Used in Anti-Ageing Trial

Pet Dogs to Be Used in Anti-Ageing Trial

Reuters - Innovations Video Online (Nov. 26, 2014) — Researchers in the United States are preparing to discover whether a drug commonly used in human organ transplants can extend the lifespan and health quality of pet dogs. Video provided by Reuters
Powered by NewsLook.com
Today's Prostheses Are More Capable Than Ever

Today's Prostheses Are More Capable Than Ever

Newsy (Nov. 26, 2014) — Advances in prosthetics are making replacement body parts stronger and more lifelike than they’ve ever been. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:

Strange & Offbeat Stories

 

Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins